Benchmarking progression-free survival ratio as primary endpoint in precision oncology clinical trials. - Nichetti F; Hüllein J; du Rusquec P; Pleasance E; Chen L; Mock A; Horak P; Ambrosini P; Rota S; Niger M; Agnelli L; Tinè G; et al. (NPJ precision oncology, 2025)